Pegylated interferon α-2b plus ribavirin for Japanese chronic hepatitis C patients with normal alanine aminotransferase

Mosaburo Kainuma, Norihiro Furusyo, Koichi Azuma, Eiji Kajiwara, Kazuhiro Takahashi, Hideyuki Nomura, Yuichi Tanabe, Takeaki Satoh, Toshihiro Maruyama, Makoto Nakamuta, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aim: To investigate the efficacy and safety of a pegylated interferon (PEG-IFN) α-2b plus ribavirin (RBV) combination treatment for patients with chronic hepatitis C virus (HCV) infection who have persistently normal alanine aminotransferase (NALT). Methods: This multicenter study included 989 patients with HCV genotype 1 (114 with NALT and 875 with elevated ALT) who received weight-based doses of PEG-IFN α-2b plus RBV for 48weeks. We compared the sustained viral response (SVR) rates of patients with NALT and elevated ALT who received at least 80% or more of the target dosage of PEG-IFN α-2b and 60% or more of the target RBV (minimum acceptable dosage). Results: No significant difference was found in the overall SVR rate between the NALT (42.1%) and elevated ALT groups (37.3%). No significant difference in the SVR rates was found between NALT (63.3%) and elevated ALT group (61.6%) patients who received minimum acceptable dosage. Multivariate analysis showed that age (<65years old) and total cholesterol (≧220mg/dL) were significantly independent positive factors associated with an SVR in the NALT group. Twenty-four weeks after treatment, an ALT increase above the normal range was observed for 34.0% (18 of 53) of the non-responsive group of NALT patients. Conclusions: The efficacy and safety of PEG-IFN α-2b plus RBV combination therapy for patients with chronic HCV infection are similar for patients with NALT and those with elevated ALT levels. These results indicate that patients with NALT should be considered for treatment with PEG-IFN α-2b plus RBV.

Original languageEnglish
Pages (from-to)33-41
Number of pages9
JournalHepatology Research
Volume42
Issue number1
DOIs
Publication statusPublished - Jan 1 2012

Fingerprint

Ribavirin
Chronic Hepatitis C
Alanine Transaminase
Interferons
Hepacivirus
Virus Diseases
Safety
Therapeutics
Multicenter Studies
Reference Values
Multivariate Analysis
Cholesterol
Genotype
Weights and Measures

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Infectious Diseases

Cite this

Pegylated interferon α-2b plus ribavirin for Japanese chronic hepatitis C patients with normal alanine aminotransferase. / Kainuma, Mosaburo; Furusyo, Norihiro; Azuma, Koichi; Kajiwara, Eiji; Takahashi, Kazuhiro; Nomura, Hideyuki; Tanabe, Yuichi; Satoh, Takeaki; Maruyama, Toshihiro; Nakamuta, Makoto; Kotoh, Kazuhiro; Shimoda, Shinji; Hayashi, Jun.

In: Hepatology Research, Vol. 42, No. 1, 01.01.2012, p. 33-41.

Research output: Contribution to journalArticle

Kainuma, M, Furusyo, N, Azuma, K, Kajiwara, E, Takahashi, K, Nomura, H, Tanabe, Y, Satoh, T, Maruyama, T, Nakamuta, M, Kotoh, K, Shimoda, S & Hayashi, J 2012, 'Pegylated interferon α-2b plus ribavirin for Japanese chronic hepatitis C patients with normal alanine aminotransferase', Hepatology Research, vol. 42, no. 1, pp. 33-41. https://doi.org/10.1111/j.1872-034X.2011.00907.x
Kainuma, Mosaburo ; Furusyo, Norihiro ; Azuma, Koichi ; Kajiwara, Eiji ; Takahashi, Kazuhiro ; Nomura, Hideyuki ; Tanabe, Yuichi ; Satoh, Takeaki ; Maruyama, Toshihiro ; Nakamuta, Makoto ; Kotoh, Kazuhiro ; Shimoda, Shinji ; Hayashi, Jun. / Pegylated interferon α-2b plus ribavirin for Japanese chronic hepatitis C patients with normal alanine aminotransferase. In: Hepatology Research. 2012 ; Vol. 42, No. 1. pp. 33-41.
@article{07cdec5c2576476197910a801a5808ac,
title = "Pegylated interferon α-2b plus ribavirin for Japanese chronic hepatitis C patients with normal alanine aminotransferase",
abstract = "Aim: To investigate the efficacy and safety of a pegylated interferon (PEG-IFN) α-2b plus ribavirin (RBV) combination treatment for patients with chronic hepatitis C virus (HCV) infection who have persistently normal alanine aminotransferase (NALT). Methods: This multicenter study included 989 patients with HCV genotype 1 (114 with NALT and 875 with elevated ALT) who received weight-based doses of PEG-IFN α-2b plus RBV for 48weeks. We compared the sustained viral response (SVR) rates of patients with NALT and elevated ALT who received at least 80{\%} or more of the target dosage of PEG-IFN α-2b and 60{\%} or more of the target RBV (minimum acceptable dosage). Results: No significant difference was found in the overall SVR rate between the NALT (42.1{\%}) and elevated ALT groups (37.3{\%}). No significant difference in the SVR rates was found between NALT (63.3{\%}) and elevated ALT group (61.6{\%}) patients who received minimum acceptable dosage. Multivariate analysis showed that age (<65years old) and total cholesterol (≧220mg/dL) were significantly independent positive factors associated with an SVR in the NALT group. Twenty-four weeks after treatment, an ALT increase above the normal range was observed for 34.0{\%} (18 of 53) of the non-responsive group of NALT patients. Conclusions: The efficacy and safety of PEG-IFN α-2b plus RBV combination therapy for patients with chronic HCV infection are similar for patients with NALT and those with elevated ALT levels. These results indicate that patients with NALT should be considered for treatment with PEG-IFN α-2b plus RBV.",
author = "Mosaburo Kainuma and Norihiro Furusyo and Koichi Azuma and Eiji Kajiwara and Kazuhiro Takahashi and Hideyuki Nomura and Yuichi Tanabe and Takeaki Satoh and Toshihiro Maruyama and Makoto Nakamuta and Kazuhiro Kotoh and Shinji Shimoda and Jun Hayashi",
year = "2012",
month = "1",
day = "1",
doi = "10.1111/j.1872-034X.2011.00907.x",
language = "English",
volume = "42",
pages = "33--41",
journal = "Hepatology Research",
issn = "1386-6346",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Pegylated interferon α-2b plus ribavirin for Japanese chronic hepatitis C patients with normal alanine aminotransferase

AU - Kainuma, Mosaburo

AU - Furusyo, Norihiro

AU - Azuma, Koichi

AU - Kajiwara, Eiji

AU - Takahashi, Kazuhiro

AU - Nomura, Hideyuki

AU - Tanabe, Yuichi

AU - Satoh, Takeaki

AU - Maruyama, Toshihiro

AU - Nakamuta, Makoto

AU - Kotoh, Kazuhiro

AU - Shimoda, Shinji

AU - Hayashi, Jun

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Aim: To investigate the efficacy and safety of a pegylated interferon (PEG-IFN) α-2b plus ribavirin (RBV) combination treatment for patients with chronic hepatitis C virus (HCV) infection who have persistently normal alanine aminotransferase (NALT). Methods: This multicenter study included 989 patients with HCV genotype 1 (114 with NALT and 875 with elevated ALT) who received weight-based doses of PEG-IFN α-2b plus RBV for 48weeks. We compared the sustained viral response (SVR) rates of patients with NALT and elevated ALT who received at least 80% or more of the target dosage of PEG-IFN α-2b and 60% or more of the target RBV (minimum acceptable dosage). Results: No significant difference was found in the overall SVR rate between the NALT (42.1%) and elevated ALT groups (37.3%). No significant difference in the SVR rates was found between NALT (63.3%) and elevated ALT group (61.6%) patients who received minimum acceptable dosage. Multivariate analysis showed that age (<65years old) and total cholesterol (≧220mg/dL) were significantly independent positive factors associated with an SVR in the NALT group. Twenty-four weeks after treatment, an ALT increase above the normal range was observed for 34.0% (18 of 53) of the non-responsive group of NALT patients. Conclusions: The efficacy and safety of PEG-IFN α-2b plus RBV combination therapy for patients with chronic HCV infection are similar for patients with NALT and those with elevated ALT levels. These results indicate that patients with NALT should be considered for treatment with PEG-IFN α-2b plus RBV.

AB - Aim: To investigate the efficacy and safety of a pegylated interferon (PEG-IFN) α-2b plus ribavirin (RBV) combination treatment for patients with chronic hepatitis C virus (HCV) infection who have persistently normal alanine aminotransferase (NALT). Methods: This multicenter study included 989 patients with HCV genotype 1 (114 with NALT and 875 with elevated ALT) who received weight-based doses of PEG-IFN α-2b plus RBV for 48weeks. We compared the sustained viral response (SVR) rates of patients with NALT and elevated ALT who received at least 80% or more of the target dosage of PEG-IFN α-2b and 60% or more of the target RBV (minimum acceptable dosage). Results: No significant difference was found in the overall SVR rate between the NALT (42.1%) and elevated ALT groups (37.3%). No significant difference in the SVR rates was found between NALT (63.3%) and elevated ALT group (61.6%) patients who received minimum acceptable dosage. Multivariate analysis showed that age (<65years old) and total cholesterol (≧220mg/dL) were significantly independent positive factors associated with an SVR in the NALT group. Twenty-four weeks after treatment, an ALT increase above the normal range was observed for 34.0% (18 of 53) of the non-responsive group of NALT patients. Conclusions: The efficacy and safety of PEG-IFN α-2b plus RBV combination therapy for patients with chronic HCV infection are similar for patients with NALT and those with elevated ALT levels. These results indicate that patients with NALT should be considered for treatment with PEG-IFN α-2b plus RBV.

UR - http://www.scopus.com/inward/record.url?scp=84055193435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84055193435&partnerID=8YFLogxK

U2 - 10.1111/j.1872-034X.2011.00907.x

DO - 10.1111/j.1872-034X.2011.00907.x

M3 - Article

VL - 42

SP - 33

EP - 41

JO - Hepatology Research

JF - Hepatology Research

SN - 1386-6346

IS - 1

ER -